136 related articles for article (PubMed ID: 8965998)
1. [Short- and long-term evaluation of treatment of critical ischemia of the lower lim with PGE1 (alprostadyl alpha-cyclodestrine)].
Amitrano M; Izzo M; Castaldo G; Lombardi R; Tizzano R; Bellizzi AM; Vietri GC; Sorrentino A; D'Avanzo A
Minerva Cardioangiol; 1996; 44(7-8):391-6. PubMed ID: 8965998
[TBL] [Abstract][Full Text] [Related]
2. Is transcutaneous oxygen and carbon dioxide monitoring indispensable in short- and long-term therapeutic management of non-reconstructable lower critical limb ischemia?
Melillo E; Nuti M; Pedrinelli R; Buttitta F; Balbarini A
Minerva Cardioangiol; 2006 Aug; 54(4):481-98. PubMed ID: 17016419
[TBL] [Abstract][Full Text] [Related]
3. [Effect of intra-arterial and intravenous PGE1 infusions on transcutaneous oxygen pressure in patients with critical ischemia of the extremities].
Weiss T; Griesshaber J; Rogatti W; Kistner O; Hsu E; Jansen T; Diehm C
Vasa Suppl; 1991; 33():341-2. PubMed ID: 1788749
[TBL] [Abstract][Full Text] [Related]
4. [Intra-arterial infusion of PGE1 alpha cyclodextrin].
Laurora G; Cesarone MR; Belcaro G; Incandela L; De Sanctis MT; Fascetti E; D'Archivio C
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):17-20. PubMed ID: 10658440
[TBL] [Abstract][Full Text] [Related]
5. Study of thrombinic activation indexes, in patients with lower limb critic ischaemia, before and after prostaglandin E1 therapy.
Trifiletti A; Bartolone S; Scamardi R; Pizzoleo MA; Attinà A; Sottilotta G; Canobbio V; Soraci S; Barbera N
Minerva Cardioangiol; 1999 Mar; 47(3):55-8. PubMed ID: 10389444
[TBL] [Abstract][Full Text] [Related]
6. ["Responders and non-responders" to PGE1 and alpha-cyclodextrin].
De Sanctis MT; Incandela L; Iacobitti P
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):31-6. PubMed ID: 10658442
[TBL] [Abstract][Full Text] [Related]
7. PGE1 treatment of severe skin ischemia in patients with peripheral arterial insufficiency--the effect on skin microcirculation.
Fagrell B; Lundberg G; Olsson A; Ostergren J
Vasa; 1986; 15(1):56-60. PubMed ID: 3962459
[No Abstract] [Full Text] [Related]
8. [Results of intra-arterial administration of PGE1 prostaglandin].
Ciostek P; Kostewicz W; Górski G
Wiad Lek; 1994 Oct; 47(19-20):750-2. PubMed ID: 7483622
[TBL] [Abstract][Full Text] [Related]
9. [Intravenous administration of PGE1: studies of the effectiveness and duration of the effect of various dosages based on flow measurements of the femoral artery in patients with healthy vessels and in stage IIb arterial occlusive disease].
Scheffler P; Birkel L; Grub KR; de la Hamette D
Vasa Suppl; 1988; 23():126-9. PubMed ID: 3061035
[No Abstract] [Full Text] [Related]
10. [Long-term blood pressure measurements with i.v. prostaglandin E1 infusion].
Heidrich H; Brodel C; Meuche C; Hellmann G; Ranft J
Vasa Suppl; 1989; 27():46. PubMed ID: 2623542
[No Abstract] [Full Text] [Related]
11. Prostanoids for chronic critical leg ischemia. A randomized, controlled, open-label trial with prostaglandin E1. The ICAI Study Group. Ischemia Cronica degli Arti Inferiori.
Ann Intern Med; 1999 Mar; 130(5):412-21. PubMed ID: 10068415
[TBL] [Abstract][Full Text] [Related]
12. [Intravenous and intra-arterial prostaglandin E1 treatment in patients with stage IIb arterial occlusive disease].
Rudofsky G
Vasa Suppl; 1988; 23():121-5. PubMed ID: 3206330
[No Abstract] [Full Text] [Related]
13. [Analysis of costs and results of prostaglandin (PGE1 alpha-cyclodestrin) therapy of peripheral arterial diseases].
Bucci M; Iacobitti P; Laurora G; Cesarone MR
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):9-15. PubMed ID: 10658439
[TBL] [Abstract][Full Text] [Related]
14. [Increasing transcutaneous PO2 in arteriopathies during treatment with PGE1 alpha-cyclodextrin].
Belcaro G; Cesarone MR
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):37-43. PubMed ID: 10658443
[TBL] [Abstract][Full Text] [Related]
15. PGE(1) short term therapy in critical lower limb ischemia.
Bandiera G; Forletta M; Di Paola FM; Cirielli C
Int Angiol; 2003 Mar; 22(1):58-63. PubMed ID: 12771858
[TBL] [Abstract][Full Text] [Related]
16. [Results of the treatment of peripheral arterial diseases with PGE1].
Borkowski M; Kruk M; Królicki L; Wojtal E; Malmurowicz L; Górewicz R; Laszuk D
Pol Tyg Lek; 1990 Jun 18-25; 45(25-26):505-8. PubMed ID: 2287566
[TBL] [Abstract][Full Text] [Related]
17. Outpatient treatment of severe peripheral ischemia with intravenous intermittent low-dose iloprost. An open pilot study.
Banyai S; Jenelten R; Wagner S; Allmann J; Banyai M; Koppensteiner R
Int Angiol; 2002 Mar; 21(1):36-43. PubMed ID: 11941272
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutic use of flunarizine in the treatment arteriopathies of the lower extremities].
Ambrosi V; Gabrielli F
Minerva Med; 1983 Mar; 74(13):685-9. PubMed ID: 6220230
[TBL] [Abstract][Full Text] [Related]
19. [Cardiovascular morbidity/mortality modified by the use of FGE1 alpha-cyclodextran and calcium heparin in patients with severe vascular diseases].
Belcaro G; Cesarone MR; Bucci M; Iacobitti P; Dugall M
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):55-8. PubMed ID: 10658446
[TBL] [Abstract][Full Text] [Related]
20. [Prostaglandin E1 in intermittent claudication].
Scheffler P; de la Hamette D; Rogatti W
Vasa Suppl; 1992; 35():147-8. PubMed ID: 1481022
[No Abstract] [Full Text] [Related]
[Next] [New Search]
